Abstract
Summary
A literature review identified nearly 500 papers in which references to
quality of life (QoL) were made in the context of schizophrenia. Despite
this, only two studies could be found where efforts had been made to assess
the impact of pharmaceutical products on the QoL of patients with
schizophrenia. It is argued that lack of progress in this area of research
results from the absence of an adequate schizophrenia-specific QoL
instrument. The present paper details the requirements for such an
instrument, reviews health status instruments that have been used with
schizophrenic patients and describes the methodology required for producing
a new instrument. It is argued that the pharmaceutical industry should
consider joint financing of such development work, given the importance of a
reliable, valid and responsive outcome instrument for clinical trials. Such
an instrument would also prove valuable when assessing alternative
management programmes.
Publisher
Cambridge University Press (CUP)
Subject
Psychiatry and Mental health
Cited by
48 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献